Gastric Amphicrine Carcinoma Showing Neuroendocrine and Pancreatic Acinar Cell Differentiation. Lesson from a Challenging Case Opening New Perspectives in the Diagnostic Work-Up of Gastric Neuroendocrine Neoplasms

• Published in: Endocrine pathology 2023-09, Vol.34 (3), p.349-357
• Main Authors: Sciarra, Amedeo, Uccella, Silvia, Hiroz, Philippe, Fournier, Ian, Soubeyran, Vincent, Finzi, Giovanna, La Rosa, Stefano
• Format: Article
• Language: English
• Subjects: Cancer; Case Report; Cell differentiation; Diagnosis; Endocrinology; ErbB-2 protein; Gastric cancer; Immunohistochemistry; Medicine; Medicine & Public Health; Neuroendocrine tumors; Oncology; Pancreas; Pancreatic carcinoma; Pathology; Phenotypes; Tumors
• ISSN: 1046-3976; 1559-0097
• DOI: 10.1007/s12022-023-09773-1

Amphicrine carcinomas are epithelial neoplasms composed of cells with co-existing exocrine-neuroendocrine phenotype and are challenging lesions from both diagnostic and therapeutic perspectives. Here, we report the case of a 63-year-old male patient with a gastric nodule that was endoscopically biopsied, revealing histological features of a type 3 well-differentiated gastric neuroendocrine tumor (NET). At imaging, the lesion was single and limited to the stomach, but did not present In−111 Octreotide uptake, despite SSTR2A immunohistochemical expression. The patient underwent a wedge resection of the gastric wall, with a final pathological diagnosis of amphicrine carcinoma with pancreatic acinar cell and neuroendocrine features (pT1b). Predictive immunohistochemistry showed microsatellite stability and negative HER2 status. Hotspot targeted deep sequencing of 57 genes showed no somatic mutation, in agreement with the low mutational burden reported for gastric amphicrine carcinomas. Due to a low stage of the tumor and the poor performance status of the patient, no additional oncological treatment was administered. The patient was disease-free after 18 months. This unusual case highlights the importance of considering amphicrine carcinoma in the diagnostic work-up of gastric type 3 NET. This can be done by including in the immunohistochemical panel non-neuroendocrine markers, such as the pancreatic acinar cell and glandular ones. Correct pathological diagnosis is pivotal to determine the appropriate staging (NET vs exocrine one) for surgical and oncological management.